Published in J Clin Pharmacol on January 01, 1986
Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers. Br J Clin Pharmacol (1999) 0.81
Radioimmunoassay for prednisolone. Steroids (1973) 1.81
Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol (1995) 1.43
Estimating the accumulation of drugs. J Pharm Sci (1983) 1.37
Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol (2000) 1.23
Studies of the ribosomal ribonucleic acid from mesophilic and thermophilic bacteria. Biochim Biophys Acta (1967) 1.16
Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm (1981) 1.13
Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther (1987) 1.13
Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm (1977) 1.12
Plasma protein binding of diazepam after a single dose of sodium oleate. J Pharm Sci (1978) 1.10
Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol (2000) 1.04
Pharmacokinetics of erythromycin on repetitive dosing. J Clin Pharmacol (1977) 1.04
Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther (1978) 0.98
Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol (1985) 0.97
Food increases the bioavailability of isotretinoin. J Clin Pharmacol (1984) 0.96
Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther (1990) 0.96
Renal clearance of carprofen in the isolated perfused rat kidney. Drug Metab Dispos (1981) 0.91
Red blood cell sorbitol lowering effects and tolerance of single doses of AL 1576 (HOE 843) in diabetic patients. J Clin Pharmacol (1988) 0.90
Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci (2003) 0.89
Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J Pharm Sci (1983) 0.88
Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection. J Chromatogr (1987) 0.88
An evolution of drug development and clinical pharmacology during the 20th century. J Clin Pharmacol (2000) 0.87
Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther (1982) 0.87
Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol (1988) 0.86
The clinical pharmacokinetics of quinapril. Angiology (1989) 0.86
A new radioimmunoassay for haloperidol: direct measurement of serum and striatal concentrations. J Pharmacol Exp Ther (1981) 0.85
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med (1996) 0.84
Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1988) 0.83
Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol (2001) 0.83
Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet (1985) 0.83
Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives. J Clin Pharmacol (1989) 0.82
The influence of liver dysfunction on the pharmacokinetics of carprofen. J Clin Pharmacol (1985) 0.82
Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther (2002) 0.82
Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol (1982) 0.81
Differences in oral verapamil absorption as a function of time of day. J Clin Pharmacol (1989) 0.81
Pharmacokinetic analysis of concentration-time data obtained following administration of drugs that are recycled in the bile. J Pharm Sci (1984) 0.81
Acetylation of sulfisoxazole by isolated perfused rat kidney. J Pharm Sci (1980) 0.80
Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res (1985) 0.80
Pharmacokinetic interpretation of plasma cortisol and cortisone concentrations following a signle oral administration of cortisone acetate to human subjects. J Clin Pharmacol (1980) 0.80
Theophylline dosage adjustment during enoxacin coadministration. Antimicrob Agents Chemother (1990) 0.80
Pharmacokinetics of drugs during various detoxification procedures for overdose and environmental exposure. Drug Metab Rev (1982) 0.80
Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol (1983) 0.80
Age and cibenzoline disposition. Clin Pharmacol Ther (1984) 0.80
Pharmacokinetics of multiple oral doses of selected polychlorinated biphenyls in mice. Toxicol Appl Pharmacol (1979) 0.80
Metabolism of salicylic acid in the isolated perfused rat kidney. Interconversion of salicyluric and salicyclic acids. Drug Metab Dispos (1981) 0.80
Radioimmunoassay for prednisone. Steroids (1974) 0.80
The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res (1988) 0.80
A time-dependent volume of distribution term used to describe linear concentration-time profiles. J Pharmacokinet Biopharm (1983) 0.79
Pharmacokinetics of a single intramuscular injection of vitamin E to premature neonates. Pediatr Pharmacol (New York) (1983) 0.79
Application of statistical moment theory to pharmacokinetics. J Clin Pharmacol (1988) 0.79
Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol (1999) 0.79
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin. Anesth Analg (2001) 0.79
Clinical bioavailability evaluation of a controlled release formulation of diazepam. J Pharmacokinet Biopharm (1981) 0.79
Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab Rev (1980) 0.78
Absorption of saccharin from rat urinary bladder. J Pharm Sci (1978) 0.78
A pharmacokinetic model for enterohepatic recirculation in the rat: phenolphthalein, a model drug. Drug Metab Dispos (1979) 0.78
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drug Dispos (2000) 0.78
Pharmacokinetics and pharmacodynamics of intravenous cibenzoline in normal volunteers. J Clin Pharmacol (1985) 0.78
A pharmacokinetic model to differentiate preabsorptive, gut epithelial, and hepatic first-pass metabolism. J Pharmacokinet Biopharm (1979) 0.77
Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. Drug Metab Dispos (1983) 0.77
High-performance liquid chromatographic assay of the aldose reductase inhibitor spiro-(2-fluoro-9H-fluorene-9,4'-imidazolidine)-2',5'-dione (AL01567) in plasma and urine and its pharmacokinetics in humans. J Pharm Sci (1988) 0.77
Comparison of statistical moment parameters to Cmax and tmax for detecting differences in in vivo dissolution rates. J Pharm Sci (1985) 0.77
Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharm Drug Dispos (1992) 0.77
A preliminary report on the pharmacokinetics of saccharin in man: single oral dose administration. J Clin Pharmacol (1981) 0.77
Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon. Eur J Clin Pharmacol (1985) 0.77
Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs. J Pharm Sci (1982) 0.77
Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. J Am Acad Dermatol (1982) 0.77
Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther (1980) 0.76
Pharmacokinetic model to describe the disposition of lead in the rat. J Toxicol Environ Health (1985) 0.76
Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J Pharm Sci (1984) 0.76
Pharmacokinetics of saccharin in the rat. Renal clearance in vivo and in the isolated perfused kidney. Drug Metab Dispos (1980) 0.76
Time course of carbamazepine self-induction. J Pharmacokinet Biopharm (1979) 0.76
Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. Eur J Clin Pharmacol (1983) 0.76
Dietary saccharin kinetics. Clin Pharmacol Ther (1981) 0.76
The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576. J Ocul Pharmacol (1989) 0.75
Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma. J Chromatogr (1991) 0.75
A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.75
Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am J Kidney Dis (1995) 0.75
Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. Drug Metab Dispos (1985) 0.75
Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol (1991) 0.75
D-Propoxyphene: accumulation or altered kinetics? Eur J Clin Pharmacol (1985) 0.75
Controversy. II: Bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect. J Clin Pharmacol (1988) 0.75
Evaluation of drug absorption by nonlinear regression, statistical moments, and Loo-Riegelman methods. J Pharm Sci (1985) 0.75
Curve fitting and unique parameter identification. J Pharm Sci (1987) 0.75
Balanced incomplete-block design: its use and misuse. J Pharm Sci (1985) 0.75
In vitro effect of methylprednisolone on protein synthesis of activated canine thymus-derived lymphocytes. Transplant Proc (1975) 0.75
RIV vs. CPB for prednisolone. J Pharmacokinet Biopharm (1975) 0.75
Plasma concentration profiles of human recombinant interleukin-2 (HrIL-2) in the rat following administration by various systemic routes. Drug Metab Dispos (1987) 0.75
Pharmacokinetic model of presystemic metabolism. Drug Metab Dispos (1978) 0.75
Controversy I: Patients or healthy volunteers for pharmacokinetic studies? J Clin Pharmacol (1986) 0.75
Relative bioavailability: what reference? J Pharm Sci (1986) 0.75
Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effect. J Clin Pharmacol (1986) 0.75
Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clin Pharmacokinet (1985) 0.75
Pharmacokinetic model for serum concentrations of ampicillin in the newborn infant. J Infect Dis (1976) 0.75
Effect of meals on the kinetics of etretinate. J Clin Pharmacol (1986) 0.75
Multiple-dose pharmacokinetics of diazepam following once-daily administration of a controlled-release capsule. Ther Drug Monit (1983) 0.75